论文部分内容阅读
目的:对异体骨髓间充质干细胞治疗各个时相慢加急性乙肝肝衰竭的临床治疗效果进行探讨。方法:选取该院2013年1月至2015年1月所收治的66例慢加急性乙肝肝衰竭患者作为观察的对象,按随机数字表法分成常规组与实验组,其中,前者予以常规综合治疗,在此基础之上,对后者患者予以异体骨髓间充质干细胞治疗,然后对两组患者的临床治疗情况比较。结果:两组患者进展期患者存活率相比较,差异无统计学意义(P>0.05);而组间平台期患者存活率相对比,差异显著(P<0.05);另外,实验组平台期患者存活率高于进展期,差异有统计学意义(P<0.05)。结论:在常规治疗的基础之上,对慢加急性乙肝肝衰竭患者予以异体骨髓间充质干细胞治疗,效果显著,可提升患者的存活率,尤其是平台期患者,疗效更为明显,值得在临床上大力推行与应用。
OBJECTIVE: To investigate the clinical effect of allogeneic bone marrow mesenchymal stem cells (BMSCs) in treating chronic hepatitis B with acute hepatitis B failure. Methods: Sixty-six patients with acute and chronic hepatitis B liver failure admitted from January 2013 to January 2015 in our hospital were selected as the observational subjects and divided into routine group and experimental group by random number table method. Among them, the former was treated by conventional combined therapy , On this basis, the latter patients were allogeneic bone marrow mesenchymal stem cell therapy, and then compared the clinical treatment of two groups of patients. Results: There was no significant difference in the survival rate between the two groups (P> 0.05), while the survival rate of the patients in the plateau phase was significantly different (P <0.05). In addition, the plateau patients in the experimental group The survival rate was higher than the progress, the difference was statistically significant (P <0.05). Conclusion: On the basis of routine treatment, allogeneic BMSCs are treated in patients with chronic hepatitis B and liver failure, the effect is significant, which can improve the survival rate of patients, especially in patients with plateau, the effect is more obvious Clinically vigorously promote the application.